Avastin 25 mg/ml concentrate for solution for infusion
Sponsors
Gilead Sciences Inc., Centre Hospitalier Universitaire De Grenoble, AstraZeneca AB, University Medical Center Groningen, Bristol Myers Squibb International Corporation
Conditions
Advanced Hepatobiliary CancerBarrett's esophagusMetastatic Colorectal Cancer (mCRC)Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
Metastatic Colorectal Cancer (dMMR)unresectable hepatocellular carcinoma
Phase 2
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
CompletedCTIS2022-500177-13-00
Start: 2023-06-02End: 2024-06-26Target: 46Updated: 2024-04-02
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
CompletedCTIS2022-502078-17-00
Start: 2022-12-15End: 2024-03-08Target: 196Updated: 2023-08-22
SLURP; A phase 2 intervention study: Detection of early esophageal neoplastic lesions by quantified fluorescence molecular endoscopy using oral and topical administration of bevacizumab-800CW and cetuximab-800CW
RecruitingCTIS2023-503801-12-00
Start: 2023-09-15Target: 25Updated: 2024-02-08
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)
RecruitingCTIS2022-502317-29-00
Start: 2023-07-12Target: 60Updated: 2025-12-11